Basar Oku

Association of Familial Mediterranean Fever-Related MEFV Variations With Ankylosing Spondylitis

OBJECTIVE The pathogenesis of ankylosing spondylitis (AS) has a strong genetic contribution. Familial Mediterranean fever (FMF) is an autosomal recessively inherited autoinflammatory disorder caused by MEFV gene missense variations, and a clinical association between FMF and AS has been reported previously. The aim of this study was to analyze the association of common MEFV variations (M694V, M680I, V726A, and E148Q) with AS in a group of Turkish patients. METHODS The study group comprised 193 patients with AS and 103 matched healthy control subjects. All individuals were genotyped for 4 MEFV variations and HLA-B27 using genomic DNA, and association of the variations with the clinical and laboratory features of the patients was analyzed. RESULTS The MEFV missense variations were significantly more frequent in patients with AS (22.3%) compared with healthy control subjects (9.7%; odds ratio [OR] 2.67, 95% confidence interval [95% CI] 1.28-5.56). This difference was more prominent for exon 10 variations (M694V, V726A, M680I) (OR 3.75, 95% CI 1.41-9.97), especially for the most-penetrant variation M694V (OR 4.73, 95% CI 1.39-16.12). MEFV variations were more frequent in HLA-B27-negative patients with AS, and the difference was statistically significant in patients carrying exon 10 variants. CONCLUSION FMF-related MEFV variations are associated with AS, and these variations may contribute to the pathogenesis of AS, especially in populations in which the prevalence of FMF is high.

Morphological and functional changes of blood–brain barrier in kindled rats with cortical dysplasia

Cortical dysplasia (CD) is one of the major causes contributing to epileptogenesis associated with blood-brain-barrier (BBB) disturbances. The current study investigated the functional and ultrastructural changes of BBB in pentylenetetrazole (PTZ)-kindled rats with CD. Pregnant rats on E17 were exposed to 145 cGy of gamma-irradiation and offspring were used for experiments. The rats were given PTZ three times per week to induce kindling. The permeability of BBB was determined by using sodium fluorescein (NaFlu). Immunohistochemistry for occludin, GFAP and c-fos, western-blot analysis for occludin and electron microscopy for the ultrastructural alterations in BBB were performed. The brain level of NaFlu did not increase in rats with CD and/or kindling. Following administration of a convulsive dose of PTZ, a significant increase in BBB permeability was observed in kindled rats with CD. Occludin immunoreactivity and expression remained essentially unchanged in all groups. Slightly enhanced immunoreactivity for GFAP was observed in all groups except control. c-fos immunoreactivity in brain sections of kindled rats with CD displayed a striking increase by convulsive PTZ challenge. Tight junctions were ultrastructurally intact, whereas markedly increased number of pinocytotic vesicles was noted in brain endothelium of kindled rats with CD by convulsive dose of PTZ. The present study showed that epileptic seizures induced by convulsive PTZ challenge during kindling-mediated epileptogenesis in the presence of CD changed both functional and ultrastructural properties of the BBB and considerably enhanced transendothelial vesicular transport, while paracellular pathway was apparently not involved in this setting.

No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behçet’s disease

Behçet’s disease (BD) is a multisystem inflammatory disorder of unknown etiology, and infections with different microorganisms including streptococci have been claimed as triggers of inflammatory attacks in BD pathogenesis. Toll-like receptor 2 (TLR2) has been known to recognize several microbial antigens including that of streptococci, and TLR2 gene Arg753Gln polymorphism has been reported to be strongly associated with acute rheumatic fever with an odds ratio of 100. This study aimed to investigate the TLR2 gene Arg753Gln polymorphism in a group of patients with BD and rheumatic heart disease (RHD) and to analyze the role of genotyping errors resulting from duplicated gene segments. The study group consisted of 211 patients with BD, 95 patients with RHD, and 94 matched Turkish healthy controls. Because of the duplicated exon 3 in 23-kb upstream of the TLR2 gene, genotyping for the Arg753Gln polymorphism with polymerase chain reaction–restriction fragment length polymorphism method was carried out using a new set of primers and PstI restriction enzyme. TLR2 gene Gln753 allele was observed in two of 211 (1.0%) patients with BD, five of 95 (5.3%) patients with RHD, and two of 94 (2.1%) healthy controls. All patients and controls were found to be heterozygous for Arg753Gln polymorphism, except one patient with BD, who was homozygous for Gln753. Although a slight increase of heterozygosity was noted in patients with RHD, no statistically significant difference was observed in the distribution of Arg753Gln polymorphism in BD and RHD compared to healthy controls. In conclusion, TLR2 gene Arg753Gln polymorphism is not associated with BD nor with RHD; and a duplicated region of the TLR2 exon 3 located 23-kb upstream of the polymorphic region may explain contradictory association findings described so far.

The association between P selectin glycoprotein ligand 1 gene variable number of tandem repeats polymorphism and risk of thrombosis in Behçet's disease

Behçets disease (BD) has been recognized as an unclassified type of vasculitis with an accompanying tendency to thrombosis. No disease‐specific pathology has been demonstrated so far to explain the prothrombotic state, and this predisposition is considered to be associated with endothelial activation/dysfunction. P‐selectin glycoprotein ligand‐1 (PSGL‐1) variable number of tandem repeat (VNTR) polymorphism has an impact on the protein length, and heterozygosity affect of the PSGL‐1 to P‐selectin interaction, which has been found to be associated with an increased risk of thrombosis in patients with antiphospholipid syndrome. We aimed to analyze the association of PSGL‐1 gene polymorphism, in a group of BD patients with and without thrombosis.

Hypoxia Induces Erythropoietin Receptor Expression on K562 Cell Line

ABSTRACT The erythropoietin receptor (EpoR) and erythropoietin (Epo) mediate erythropoietin-induced erythroblast proliferation, differentiation and survival. This study examined the effects of the expression of EpoR on K562 (erythroleukemia) cells upon normoxia and hypoxia. In addition, the impact of the combined effect of recombinant human Epo and hypoxia was investigated. K562 (erythroleukemia) cells and as control group HL60 (promyeloblast) cells were cultured. Hypoxic incubation was performed with 5% O2, 5% CO2 and balance Nitrogen for 24 hours. After 24 hours, K562 and HL60 cells were transferred to normoxic and 5% hypoxic conditions. Recombinant Erythropoietin-alpha was added (10 U/ml) to the cells at the beginning of the experiment. Cultured cells were subjected to viability analysis, total RNA isolation, and protein isolation at three timepoints: 3 h, 6 h, and 24 h. Viability was analysed with a trypan blue exclusion using the Vi-Cell automated cell viability system. RT-PCR and western blot results of normoxic and hypoxic K562 and HL60 cell lines with/without rhEPO were compared. We showed that hypoxia upregulates the expression of EpoR on K562 erythroleukemia cells, and longer exposition to hypoxia turns the upregulated EpoR expression to basal levels. Recombinant human Epo (rhEpo) did not produce further impact in hypoxia-induced upregulation of EpoR neither in normoxia nor in hypoxia. Although addition of the rhEpo caused change in expression of cell-cycle regulators, it seems not to effect cell proliferation or cell viability. In the HL60 cell line, however, we detected EpoR mRNA, but not Epo mRNA by RT-PCR. Hypoxia did not alter the level of EpoR mRNA expression. The results of this study suggest that the expression of EpoR might be regulated by hypoxia, but not by Epo, and the expression of cell-cycle regulators might be regulated by both hypoxia and Epo.